GB0800741D0 - Cyclic triazo and diazo sodium channel blockers - Google Patents

Cyclic triazo and diazo sodium channel blockers

Info

Publication number
GB0800741D0
GB0800741D0 GBGB0800741.1A GB0800741A GB0800741D0 GB 0800741 D0 GB0800741 D0 GB 0800741D0 GB 0800741 A GB0800741 A GB 0800741A GB 0800741 D0 GB0800741 D0 GB 0800741D0
Authority
GB
United Kingdom
Prior art keywords
sodium channel
channel blockers
triazo
cyclic
diazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0800741.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Greenwich
Original Assignee
University of Greenwich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Greenwich filed Critical University of Greenwich
Priority to GBGB0800741.1A priority Critical patent/GB0800741D0/en
Publication of GB0800741D0 publication Critical patent/GB0800741D0/en
Priority to PCT/GB2009/050033 priority patent/WO2009090431A1/en
Priority to ES15185526T priority patent/ES2953286T3/es
Priority to AU2009205396A priority patent/AU2009205396B2/en
Priority to EP15185526.9A priority patent/EP3002280B1/en
Priority to CA2712070A priority patent/CA2712070C/en
Priority to US12/811,884 priority patent/US8691818B2/en
Priority to KR1020107017361A priority patent/KR101600636B1/ko
Priority to ES09701748.7T priority patent/ES2565023T3/es
Priority to JP2010542694A priority patent/JP5473944B2/ja
Priority to CN2009801023991A priority patent/CN101918378B/zh
Priority to EP09701748.7A priority patent/EP2229371B1/en
Priority to CN201310579107.1A priority patent/CN103705519B/zh
Priority to IL206815A priority patent/IL206815A/en
Priority to US14/174,492 priority patent/US9422253B2/en
Priority to US15/201,885 priority patent/US9862691B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • C07D253/10—Condensed 1,2,4-triazines; Hydrogenated condensed 1,2,4-triazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
GBGB0800741.1A 2008-01-16 2008-01-16 Cyclic triazo and diazo sodium channel blockers Ceased GB0800741D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB0800741.1A GB0800741D0 (en) 2008-01-16 2008-01-16 Cyclic triazo and diazo sodium channel blockers
CN201310579107.1A CN103705519B (zh) 2008-01-16 2009-01-16 环状叠氮和重氮钠通道阻滞剂
US12/811,884 US8691818B2 (en) 2008-01-16 2009-01-16 Cyclic triazo and diazo sodium channel blockers
ES09701748.7T ES2565023T3 (es) 2008-01-16 2009-01-16 Bloqueantes del canal de sodio diazoicos y triazoicos cíclicos
AU2009205396A AU2009205396B2 (en) 2008-01-16 2009-01-16 Cyclic triazo and diazo sodium channel blockers
EP15185526.9A EP3002280B1 (en) 2008-01-16 2009-01-16 Cyclic triazo and diazo sodium channel blockers
CA2712070A CA2712070C (en) 2008-01-16 2009-01-16 Cyclic triazo and diazo sodium channel blockers
PCT/GB2009/050033 WO2009090431A1 (en) 2008-01-16 2009-01-16 Cyclic triazo and diazo sodium channel blockers
KR1020107017361A KR101600636B1 (ko) 2008-01-16 2009-01-16 환 트리아조 및 디아조 나트륨 채널 차단제
ES15185526T ES2953286T3 (es) 2008-01-16 2009-01-16 Bloqueadores cíclicos de los canales de sodio triazo y diazo
JP2010542694A JP5473944B2 (ja) 2008-01-16 2009-01-16 環式トリアゾおよびジアゾナトリウムチャネル遮断薬
CN2009801023991A CN101918378B (zh) 2008-01-16 2009-01-16 环状叠氮和重氮钠通道阻滞剂
EP09701748.7A EP2229371B1 (en) 2008-01-16 2009-01-16 Cyclic triazo and diazo sodium channel blockers
IL206815A IL206815A (en) 2008-01-16 2010-07-05 Blockers of Triazo and Cyclo Diazu channels, pharmaceuticals including them and their use in the preparation of drugs for the treatment of diseases
US14/174,492 US9422253B2 (en) 2008-01-16 2014-02-06 Cyclic triazo and diazo sodium channel blockers
US15/201,885 US9862691B2 (en) 2008-01-16 2016-07-05 Cyclic triazo and diazo sodium channel blockers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0800741.1A GB0800741D0 (en) 2008-01-16 2008-01-16 Cyclic triazo and diazo sodium channel blockers

Publications (1)

Publication Number Publication Date
GB0800741D0 true GB0800741D0 (en) 2008-02-20

Family

ID=39144997

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0800741.1A Ceased GB0800741D0 (en) 2008-01-16 2008-01-16 Cyclic triazo and diazo sodium channel blockers

Country Status (11)

Country Link
US (3) US8691818B2 (enExample)
EP (2) EP3002280B1 (enExample)
JP (1) JP5473944B2 (enExample)
KR (1) KR101600636B1 (enExample)
CN (2) CN103705519B (enExample)
AU (1) AU2009205396B2 (enExample)
CA (1) CA2712070C (enExample)
ES (2) ES2565023T3 (enExample)
GB (1) GB0800741D0 (enExample)
IL (1) IL206815A (enExample)
WO (1) WO2009090431A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0800741D0 (en) * 2008-01-16 2008-02-20 Univ Greenwich Cyclic triazo and diazo sodium channel blockers
GB2471729A (en) * 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
GB2471713A (en) * 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
US8809525B2 (en) * 2010-02-05 2014-08-19 Heptares Therapeutics Limited 1,2,4-triazine-4-amine derivatives
WO2012019106A2 (en) * 2010-08-06 2012-02-09 Board Of Regents Of The University Of Nebraska Positive and negative modulators of nmda receptors
CN104341386A (zh) * 2013-07-23 2015-02-11 中国科学院上海药物研究所 一类芳基杂环小分子化合物、其衍生物及其制备方法和用途
US10576086B2 (en) * 2015-06-12 2020-03-03 University Of Greenwich Triazine derivatives as interferon-gamma inhibitors
AU2018302178A1 (en) 2017-07-18 2020-02-13 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
WO2019018584A1 (en) * 2017-07-18 2019-01-24 GiraFpharma LLC HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
CN107915633A (zh) * 2017-12-06 2018-04-17 安徽绩溪县徽煌化工有限公司 一种间苄氧基苯甲酸甲酯的制备方法
PL424999A1 (pl) * 2018-03-22 2019-09-23 Glg Pharma Spółka Akcyjna Farmaceutycznie akceptowalna sól 5-(4-chlorofenylo)-6-etylo-2,4- pirymidynodiaminy
US11254670B2 (en) 2019-01-18 2022-02-22 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
KR20210116550A (ko) 2019-01-18 2021-09-27 누베이션 바이오 인크. 아데노신 길항제로서의 헤테로시클릭 화합물
GB202006076D0 (en) 2020-04-24 2020-06-10 Univ Greenwich Interleukin inhibitors
GB202006080D0 (en) 2020-04-24 2020-06-10 Univ Greenwich Cytokine storm syndrome
CA3199909A1 (en) * 2020-11-23 2022-05-27 Steven HOCHWALD Compounds and methods to target glucose-stimulated phosphohistidine signaling and esophageal cancer growth
KR20250030934A (ko) * 2023-08-25 2025-03-05 제일약품주식회사 Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB759014A (en) 1952-02-26 1956-10-10 Wellcome Found Improvements in triazines and their manufacture
US3637688A (en) * 1970-01-09 1972-01-25 American Home Prod 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines
JPS5625170A (en) * 1979-06-01 1981-03-10 Wellcome Found Triazine derivative
CA1133938A (en) * 1979-06-01 1982-10-19 Martin G. Baxter Substituted aromatic compounds
IE49823B1 (en) * 1979-06-01 1985-12-25 Wellcome Found 1,2,4-triazine derivatives,process for preparing such compounds and pharmaceutical compositions containing them
DE3069556D1 (en) * 1979-08-16 1984-12-06 Wellcome Found Solid pharmaceutical formulation containing substitued phenyl-triazines
GB8328757D0 (en) * 1983-10-27 1983-11-30 Wellcome Found Chemical compounds
FI895821A7 (fi) 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
GB9012312D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
US5502054A (en) * 1994-08-11 1996-03-26 Fmc Corporation 6-substituted-3,5-diamino-1,2,4-triazines as insecticides
MA26473A1 (fr) 1997-03-01 2004-12-20 Glaxo Group Ltd Composes pharmacologiquement actifs.
DE10134980C2 (de) * 2001-07-17 2003-05-28 Helm Ag Verfahren zur Herstellung von Lamotrigin
HU225667B1 (en) 2002-09-20 2007-05-29 Richter Gedeon Nyrt Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
GB0300783D0 (en) * 2003-01-14 2003-02-12 Btg Int Ltd Treatment of neurodegenerative conditions
GB0613836D0 (en) * 2006-07-13 2006-08-23 Univ Greenwich New medical use of triazine derivatives
GB0800741D0 (en) * 2008-01-16 2008-02-20 Univ Greenwich Cyclic triazo and diazo sodium channel blockers
GB2471713A (en) * 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
GB2471729A (en) * 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers

Also Published As

Publication number Publication date
EP3002280A1 (en) 2016-04-06
CN101918378B (zh) 2013-12-04
US20110009413A1 (en) 2011-01-13
CA2712070A1 (en) 2009-07-23
JP5473944B2 (ja) 2014-04-16
US20140155403A1 (en) 2014-06-05
IL206815A0 (en) 2010-12-30
AU2009205396A1 (en) 2009-07-23
CN101918378A (zh) 2010-12-15
EP2229371B1 (en) 2015-12-23
JP2011509992A (ja) 2011-03-31
KR20100114512A (ko) 2010-10-25
ES2953286T3 (es) 2023-11-10
IL206815A (en) 2017-01-31
CN103705519A (zh) 2014-04-09
US8691818B2 (en) 2014-04-08
US9862691B2 (en) 2018-01-09
CN103705519B (zh) 2017-04-19
US20160311784A1 (en) 2016-10-27
AU2009205396B2 (en) 2014-10-02
EP3002280B1 (en) 2023-05-24
EP2229371A1 (en) 2010-09-22
CA2712070C (en) 2017-09-19
WO2009090431A1 (en) 2009-07-23
US9422253B2 (en) 2016-08-23
KR101600636B1 (ko) 2016-03-07
ES2565023T3 (es) 2016-03-30

Similar Documents

Publication Publication Date Title
GB0800741D0 (en) Cyclic triazo and diazo sodium channel blockers
EP2417756A4 (en) IMPROVED COMMUNICATION BRIDGE
EP2260175A4 (en) WELL CAP
GB2469403B (en) Slim-hole parasite string
TWI372520B (en) Reference buffer circuit
GB2459733B (en) Clock configuration
EP2351716A4 (en) GLASS
IL217330A0 (en) Cyclic triazo sodium channel blockers
EP2282849A4 (en) SPECIAL EFFECT GLAZING
GB0812210D0 (en) Glazing
AU322708S (en) Eyewear
GB2466716B (en) Output window
IL217331A0 (en) Cyclic triazo sodium channel blockers
GB0803569D0 (en) Glazing arrangement
GB2456612B (en) Optical structure
GB0912277D0 (en) Cyclic triazo and diazo sodium channel blockers 2A
GB0911992D0 (en) Cyclic triazo and diazo sodium channel blockers 2
GB0911996D0 (en) Cyclic triazo and diazo sodium channel blockers 6
GB0911994D0 (en) Cyclic triazo and diazo sodium channel blockers 4
PL2199506T3 (pl) Okno
HK1142606A (en) Cyclic triazo and diazo sodium channel blockers
GB2491743B (en) Telecommunications module
AU322707S (en) Eyewear
HK1170727A (en) Cyclic triazo sodium channel blockers
GB0911912D0 (en) Cyclic triazo sodium channel blockers 5A

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)